RxDoctor Payments Data

Montressa Phillips

Family · Charlotte, NCNPI 1881350684

Payments from drug & device makers

$909in general payments, 2019–2025

Across 38 payments — averaging $23.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$448
  • Novo Nordisk$84
  • AbbVie$78
  • Lilly USA, LLC$70
  • Pfizer$38
  • Shield Therapeutics Inc$37
  • plus $155 from 8 others

What the payments were for

  • Food & beverage$909100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$909 in reported general payments places this provider in the 65th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$5,107
Medicare patients
36
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol22$19,936
OzempicSemaglutide13$19,339
Fluticasone Propionate55$846
Azelastine Hcl25$552
Atorvastatin Calcium56$485
Omeprazole19$300
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide15$242
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav30$191
Ibuprofen17$178
Amlodipine Besylate71$161
Gabapentin14$147
Glipizide ErGlipizide13$138
Pravastatin Sodium16$125
Methylprednisolone14$119
Metformin Hcl25$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$448$19,93622 claims
Novo NordiskOzempic$84$19,33913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,522 family providers in North Carolina.

Other family in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →